Is Pfizer Stock Undervalued at Current Prices? - sharewise

Jan 5, 2025 · The price for the Pfizer Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.115 (-0.440%). With 28 Buy predictions and 1 Sell predictions Pfizer Inc. is one of the favorites of our community. With a target price of 40 € there is a hugely positive …

440%
OFF

Is Pfizer Stock Undervalued At Current Prices? - Sharewise

2 weeks from now

sharewise.com

07%
OFF

Is Pfizer Stock Undervalued At Current Prices? | The Motley Fool

2 weeks from now

Jan 5, 2025 · Pfizer (PFE-0.07%) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices used were the afternoon prices of Jan. 1, 2025. The …

fool.com

$26
OFF

Is Pfizer Stock Undervalued? - Forbes

2 weeks from now

Dec 18, 2024 · At its current levels of $26, PFE stock trades at under 9x expected earnings of $2.94 per share in 2025, versus the stock’s average P/E ratio of 14x over the last five years. …

forbes.com

59%
OFF

Unveiling Pfizer (PFE)'s Value: Is It Really Priced Right? A ...

2 weeks from now

Sep 29, 2023 · Pfizer's cash-to-debt ratio is 0.69, which is lower than 54.59% of 1057 companies in the Drug Manufacturers industry. The overall financial strength of Pfizer is 6 out of 10, …

yahoo.com

600%
OFF

Is Pfizer Stock Still A Buy After An Unexpected Setback? - Sharewise

2 weeks from now

Aug 26, 2024 · Pfizer Inc. gained 0.600% compared to yesterday. The stock is one of the favorites of our community with 27 Buy predictions and 1 Sell predictions. As a result the target price of …

sharewise.com

40%
OFF

Is Pfizer Stock Undervalued At $40? - Nasdaq

2 weeks from now

Mar 16, 2023 · We estimate Pfizer’s Valuation to be $56 per share, reflecting a significant 40% upside from the current market price of $40. While PFE stock looks undervalued, it is helpful to …

nasdaq.com

$36.00
OFF

Pfizer’s Stock Buy Rating: Undervalued With Growth Potential And ...

2 weeks from now

Oct 7, 2024 · Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Pfizer (PFE – Research Report). The associated price target remains the same with $36.00. The …

businessinsider.com

$30
OFF

Pfizer: 4 Reasons To Buy This Stock - Sharewise

2 weeks from now

Dec 31, 2024 · Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to …

sharewise.com

40%
OFF

What To Expect From PFE Stock In 2025? - Forbes

2 weeks from now

13 hours ago · We think PFE stock is now undervalued. We estimate Pfizer’s valuation to be around $36 per share, reflecting around 40% upside from its current levels. The optimism …

forbes.com

52%
OFF

Pfizer Inc. Stock - Target Price: 40 - Sharewise

2 weeks from now

With 27 Buy predictions and 1 Sell predictions Pfizer Inc. is one of the favorites of our community. With a target price of 40 € there is a hugely positive potential of 53.52% for Pfizer Inc. …

sharewise.com

2%
OFF

Is Pfizer’s Hidden Value Ignored By Wall Street - Financhill

2 weeks from now

Of the 22 analysts covering the stock, the consensus price target is $41.14, suggesting Pfizer is 24.2% undervalued. Twelve analysts rate the stock as a buy, with one of those analysts …

financhill.com

90%
OFF

Pfizer (PFE) P/E Ratio: Current & Historical Analysis - Public.com

2 weeks from now

2 days ago · The P/E ratio for Pfizer (PFE) is 35.50 as of Jan 14, 2025.This represents a decrease of-130.90% compared to its 12-month average P/E ratio of-114.89.A higher P/E ratio …

public.com

FAQs about Is Pfizer Stock Undervalued at Current Prices? - sharewise Coupon?

Is Pfizer stock undervalued?

On the other hand, if the share price is significantly below the GF Value calculation, the stock may be undervalued and have higher future returns. At its current price of $ 33.94 per share, Pfizer stock is believed to be significantly undervalued. ...

Should you buy Pfizer (PFE) stock?

Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Pfizer (PFE – Research Report). The associated price target remains the same with $36.00. Evan Seigerman has given his Buy rating due to a combination of factors indicating that Pfizer’s stock is undervalued compared to its U.S. BioPharma peers. ...

Is Pfizer's stock a buy?

Pfizer's Stock Is a Buy. Here Are Six Reasons Why. Pfizer may be one of the biggest bargains in the market today. The drugmaker offers an attractive yield, a rock-bottom valuation, and an underappreciated cancer pipeline. Long-term investors shouldn't hesitate to add this top dividend stock to their portfolios right now. ...

Is Pfizer (PFE) undervalued?

According to our valuation method, Pfizer ( NYSE:PFE) appears to be significantly undervalued. This assessment is based on historical multiples, an internal adjustment factor based on Pfizer's past business growth, and analyst estimates of future business performance. ...

Is PFE stock undervalued?

We maintain our view that PFE stock is undervalued despite its recent rise. At its current levels of $26, PFE stock trades at under 9x expected earnings of $2.94 per share in 2025, versus the stock’s average P/E ratio of 14x over the last five years. This is much lower than some of its peers. ...

Why is Pfizer stock weighing down?

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a hit in recent years and the company has been looking to bridge the revenue gap. The company looked at inorganic growth and acquired Seagen, Global Blood Therapeutics, and Biohaven, among others in the last two years or so. ...